CAP Proposes Improved Oversight of Lab-Devel...(therapy. laboratory perform...),Health

Date:9/24/2009

therapy. laboratory performed appropriate validation studies. The test presents low risk to patients. -------------- ------------------- ------------------- --------- Moderate The test result is The laboratory must KRAS Risk often used for submit validation HER2 predicting disease studies to the progression or accreditor for an identifying external review prior whether a patient to offering the test is eligible for a clinically. specific therapy The laboratory may make claims about clinical accuracy or clinical utility. The test has higher risk to patients. -------------- ------------------- ------------------- --------- High The test result The laboratory must Oncotype Risk predicts risk, submit a high-risk Dx(R) progression, test to FDA for review patient prior to offering the eligibility for a test clinically. specific therapy, AND; The test uses proprietary algorithms or computations such that the test result cannot be tied to the methods used; or inter-laboratory comparisons can not be performed. The test poses
'/>"/>

SOURCE College of American Pathologists Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine news :

1. FDA Proposes New Rules for Sunscreens
2. Carnegie Mellon neuroscientist proposes new theory of brain flexibility
3. Lake Forest Hospital Proposes a New Health Care System in Lake County
4. California Stem Cell Agency Proposes Unjustified Increase in Top Salary Ranges
5. HRSA Proposes Rule to Revise, Combine HPSAs, MUPs
6. National Patient Safety Foundation Proposes Universal Patient Compact
7. CardioDynamics Board of Directors Proposes Reverse Split 1:7 of Companys Shares
8. Governor Rendell Proposes County Grants to Combat West Nile Virus, Protect Public Health
9. Navigenics Proposes Standards for Personal Genomics Services, Coupled With Prospective Outcomes Studies, to Safeguard Consumers
10. Brandes Proposes 130 yen per Share Dividend and 10 Million Share Buyback Program for Ono Pharmaceutical Annual Meeting
11. FDA Proposes New Drug Labels for Pregnant Women